Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06751264
Active, not recruiting Not applicable

Evaluation of the Efficacy and Safety of Microwave Ablation of Uterine Adenomyosis Under Improved Ultrasound Guidance

NCT06751264 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Aerospace Center Hospital
Phase
Not applicable
Started
2025-01-20
Last updated
2026-08-03

Condition(s) studied

Adenomyosis of Uterus

Investigational drug(s) / intervention(s)

Peritoneal combined with intrauterine water isolationPeritoneal water isolation

Peritoneal combined with intrauterine water isolation: On the basis of the conventional peritoneal water isolation group, the improved technology group added additional intrauterine water isolation, and continued to inject ice saline to separate the endometrium on both sides.

Peritoneal water isolation: Transabdominal injection of saline into the abdominal cavity to achieve complete separation of the uterus from the surrounding organs and structures

Study summary

This study aims to compare the safety and efficacy of segmental power adjustment combined with uterine cavity hydro-isolation in microwave ablation of adenomyosis

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. UFs or AM diagnosed by pathology and ultrasound； 2. Relevant symptoms such asabnormal uterine bleeding, secondary anemia, progressive dysmenorrhea and enlargement of the uterus； 3. Voluntarily undergo MWA； 4. a confirmed available safe transabdominal puncture path； Exclusion Criteria: 1. Pregnancy or malignancy； 2. Severe and uncorrectable coagulation disorders； 3. Severe cardiac, liver, and renal dysfunction； 4. Anesthesia allergy.

Primary outcome measure(s)

  • The rates of endometrial injury — From enrollment to the end of treatment at 3 months
    Observe the differences in the rates of endometrial injury between two groups

Trial sites (1)

FacilityCityRegionStatus
Aerospace Center Hospital Beijing China

More Peking University Aerospace Center Hospital trials in China

The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke Starting soon
Safety and Efficacy of Microwave Ablation Alone Versus Microwave Ablation Combined With Chemical Ablation in the Treatment of Uterine Fibroids: A Prospective, Multicenter Study Starting soon

Other trials for the same condition

GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients Starting soon
Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06751264 on ClinicalTrials.gov ↗ ← All trials in China